Association Between XRCC5, 6 and 7 Gene Polymorphisms and the Risk of Breast Cancer: A HuGE Review and Meta-analysis

  • Zhou, Li-Ping (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) ;
  • Luan, Hong (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) ;
  • Dong, Xi-Hua (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) ;
  • Jin, Guo-Jiang (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) ;
  • Man, Dong-Liang (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University) ;
  • Shang, Hong (Department of Laboratory Medicine, the First Affiliated Hospital of China Medical University)
  • Published : 2012.08.31


Objective: Non-homologous end joining (NHEJ) is a pathway for repairing DNA double-strand breaks. Recent publications indicated that XRCC5, XRCC6 and XRCC7 genes may participate in the pathogenesis of breast cancer. The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to investigate associations between XRCC5, XRCC6 and XRCC7 genetic polymorphisms in the NHEJ pathway and breast cancer risk. Methods: Studies focusing on the relationship between genetic polymorphisms in XRCC5, XRCC6 and XRCC7 genes and susceptibility to breast cancer were selected from the Pubmed, Cochrane library, Embase, Web of Science, Springerlink, CNKI and CBM databases. Data were extracted by two independent reviewers. The meta-analysis was performed with Review Manager Version 5.1.6 and STATA Version 12.0 software. The odds ratio (OR) with 95% confidence interval (95%CI) was calculated based on the extracted data. Results: According to the inclusion criteria, we final included seven studies with a total of 2,864 breast cancer cases and 3,060 healthy controls. Meta-analysis results showed that rs3835 (G>A) and rs828907 (G>T) in XRCC5 gene, and rs132793 (G>A) in XRCC6 gene might increase the risk of breast cancer, while rs132788 G>T and rs6002421 (A>G) might be protective factors. However, there was no relationship between XRCC7 genetic polymorphisms and the risk of breast cancer. Conclusion: This meta-analysis suggests that the rs3835 G>A and rs828907 G>T in XRCC5 gene, rs6002421 (A>G), rs132788 (G>T) and rs132793 (G>A) in XRCC6 gene might be risk factors for breast cancer, while the rs132788 (G>T) and rs6002421 (A>G) in XRCC6 gene might be protective.


  1. Agurs-Collins T, Dunn BK, Browne D, et al (2010). Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. Semin. Oncol, 37, 384-401.
  2. Bau DT, Fu YP, Chen ST, et al (2004). Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res, 64, 5013-9.
  3. Burma S, Chen BP, Chen DJ (2006). Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst), 5, 1042-8.
  4. Burma S, Chen DJ (2004 ). Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst), 3, 909-18.
  5. Cao AY, Huang J, Hu Z, et al (2009). Mutation analysis of BRIP1/ BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat, 115, 51-5.
  6. Coughlin SS, Ekwueme DU (2009). Breast cancer as a global health concern. Cancer Epidemiol, 33, 315-8.
  7. Dapic V, Carvalho MA, Monteiro AN (2005). Breast cancer susceptibility and the DNA damage response. Cancer Control, 12, 127-36.
  8. DeSantis C, Siegel R, Bandi P, et al (2011). Breast cancer statistics, 2011. CA Cancer J Clin, 61, 409-18.
  9. Frank-Vaillant M, Marcand S (2001). NHEJ regulation by mating type is exercised through a novel protein, Lif2p, essential to the ligase IV pathway. Genes Dev, 15, 3005-12.
  10. Fu YP, Yu JC, Cheng TC, et al (2003). Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res, 63, 2440-6.
  11. Goode EL, Dunning AM, Kuschel B, et al (2002). Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res, 62, 3052-7.
  12. Grabarz A, Barascu A, Guirouilh-Barbat J, et al (2012). Initiation of DNA double strand break repair: signaling and singlestranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end joining. Am J Cancer Res, 2, 249-68.
  13. Hakem R (2008). DNA-damage repair; the good, the bad, and the ugly. EMBO J, 27, 589-605.
  14. Han J, Haiman C, Niu T, et al (2009). Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk. Hunter DJ. Breast Cancer Res Treat, 11, 613 22.
  15. Helzlsouer KJ, Harris EL, Parshad R, et al (1995). Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. Int J Cancer, 64, 14-7.
  16. He W, Luo S, Huang T, et al (2012). The Ku70 -1310C/G promoter polymorphism is associated with breast cancer susceptibility in Chinese Han population. Mol Biol Rep, 39, 577-83.
  17. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  18. Hoeijmakers JH (2009). DNA damage, aging, and cancer. N Engl J Med, 361, 1475-85.
  19. Kuschel B, Auranen A, McBride S, et al (2002). Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet, 11, 1399-407.
  20. Li Z, Luo Y, Gong Y, et al (2011). Clinical features and molecular phenotypes of breast cancer in patients with type-2 diabetes mellitus. Asian Pac J Cancer Prev, 12, 2183-8.
  21. Mao Z, Bozzella M, Seluanov A, et al (2008). DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle, 7, 2902-6.
  22. Monsees GM, Kraft P, Chanock SJ, et al (2011) Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Breast Cancer Res Treat, 125, 207-14.
  23. Parkin DM, Bray F, Ferlay J, et al (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6.
  24. Parshad R, Price FM, Bohr VA, et al (1996). Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer, 74, 1-5.
  25. Pastwa E, Błasiak J (2003). Non-homologous DNA end joining. Acta Biochim Pol, 50, 891-908.
  26. Peters JL, Sutton AJ, Jones DR,et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80.
  27. Peto J, Collins N, Barfoot R, et al (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst, 91, 943-9.
  28. Rivera-Calzada A, Spagnolo L, Pearl LH, et al (2007). Structural model of full-length human Ku70-Ku80 heterodimer and its recognition of DNA and DNA-PKcs. EMBO Rep, 8, 56-62.
  29. Shrivastav M, De Haro LP, Nickoloff JA (2008). Regulation of DNA double-strand break repair pathway choice. Cell Res, 18, 134-47.
  30. Smith TR, Levine EA, Freimanis RI et al (2008) Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis, 29, 2132-8.
  31. Sobczuk A, Smolarz B, Romanowicz H, et al (2010). Analysis of the polymorphisms in non-homologous DNA end joining (NHEJ) gene Ku70 and Ligase IV in sporadic breast cancer in women. Pol J Pathol, 61, 27-31.
  32. Spry M, Scott T, Pierce H, et al (2007). DNA repair pathways and hereditary cancer susceptibility syndromes. Front. Biosci, 12, 4191-207.
  33. von Elm E, Altman DG, Egger M, et al (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet, 370, 1453-7.
  34. Wang HC, Liu CS, Chiu CF, et al (2009). Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. Anticancer Res, 29, 5251-4.
  35. Willems P, Claes K, Baeyens A, et al (2008). Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes Cancer, 47, 137-48.
  36. Willems P, De Ruyck K, Van den Broecke R, et al (2009). A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure. J Cancer Res Clin Oncol, 135, 1159-68.
  37. Yano K, Morotomi-Yano K, Adachi N,et al (2009). Molecular mechanism of protein assembly on DNA double-strand breaks in the non-homologous end-joining pathway. J Radiat Res, 50, 97-108.
  38. Zhang L, Liu JL, Zhang YJ, et al (2011). Association between HLA-B*27 polymorphisms and ankylosing spondylitis in Han populations: a meta-analysis. Clin Exp Rheumatol, 29, 285-92.
  39. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in metaanalysis of genome searches. Genet Epidemiol, 28, 123-37.

Cited by

  1. Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Breast Cancer Risk in a Chinese Population vol.14, pp.4, 2013,
  2. Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India vol.35, pp.11, 2014,
  3. Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity vol.37, pp.2, 2016,
  4. High expression of cyclooxygenase 2 is an indicator of prognosis for patients with esophageal squamous cell carcinoma after Ivor Lewis esophagectomy vol.7, pp.3, 2016,
  5. Polymorphisms of cancer-related genes and risk of multipleprimary malignancies involving colorectal cancer vol.47, pp.13036165, 2017,